Hospitals can only watch as big players move in on primary care

The primary care business is getting more crowded at the top, where the big money is.

Last week Blue Cross and Blue Shield of Texas announced it would partner with Sanitas USA to open 10 centers offering advanced primary-care services in Dallas and Houston.

This week Forbes healthcare analyst Bruce Japsen suggested the move should worry hospitals and health systems already concerned about healthcare’s gatekeepers working under big drugstore chains and investor-backed payers.

“Health insurers are moving away from fee-for-service medicine to value-based models that pay medical care providers based on quality of care and health outcomes of patients,” Japsen wrote. “If providers and insurers are even more integrated, supporters of such arrangements believe quality and costs can be more closely monitored.”

He noted the centers in Texas will include urgent care, lab and diagnostic imaging services, wellness and disease management—and some will take walk-ins 365 days a year, welcoming patients who would otherwise go to a hospital ER.

Japsen also found patients cared for in Sanitas clinics in Florida had 32% lower hospital admission rates in 2018.

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.